[{"Assets_0_Q3_USD":734976000.0,"CommonStockSharesConverted_0_Q3_shares":73654880.0,"CommonStockSharesOutstanding_0_Q3_shares":73654880.0,"EarningsPerShareBasic_1_Q3_USD":-0.72,"EarningsPerShareBasic_3_Q3_USD":-1.85,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-107915000.0,"NetIncomeLossConverted_1_Q3_USD":-52940000.0,"NetIncomeLossConverted_3_Q3_USD":-134415000.0,"RevenuesConverted_1_Q3_USD":1101000.0,"RevenuesConverted_3_Q3_USD":19930000.0,"StockholdersEquity_0_Q3_USD":638204000.0,"Ticker":"RVMD","CIK":"1628171","name":"REVOLUTION MEDICINES, INC.","OfficialName":"Revolution Medicines Inc. Common Stock","form":"10-Q","period":"20210930","fy":"2021.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1775342076.0","Country":"United States","Sector":"Consumer Durables","Industry":"Specialty Chemicals","Market":"NASDAQ","SP500":"nan","filed":"20211110"}]